PMID- 32141343
OWN - NLM
STAT- MEDLINE
DCOM- 20210311
LR  - 20210311
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 36
IP  - 5
DP  - 2020 May
TI  - Comparative study of dulaglutide single-use pen Ateos versus insulin degludec 
      FlexTouch on learning and mock administration time in Japanese patients with type 
      2 diabetes mellitus - a post-hoc analysis.
PG  - 765-769
LID - 10.1080/03007995.2020.1739636 [doi]
AB  - Aims: Clinical data have shown that patients with diabetes require shorter 
      training time to use Ateos versus FlexTouch. Using data acquired from a previous 
      study, self-administration procedures that necessitated more time and repetition 
      during mock injection were evaluated.Methods: In this open-label task- and 
      interview-based crossover study, 48 self-injection naive participants with type 2 
      diabetes mellitus (T2DM) were randomized to 1 of 2 sequences to perform a mock 
      injection of Ateos and FlexTouch into a rubber pad after receiving training. Time 
      needed to conduct mock injection steps (preparation, pre-injection set-up, 
      injection, clean-up), and the number and time needed for repeated steps due to 
      procedural errors, were measured as post-hoc analyses.Results: Mean time for 
      preparation, injection, and clean-up was shorter for Ateos (13, 15, 9 s) versus 
      FlexTouch (96, 53, 36 s). Overall time for administration including repeated 
      steps was 75 s for Ateos and 288 s for FlexTouch. Nine participants repeated 
      procedures due to errors when using Ateos (preparation: 6; pre-injection set-up: 
      2; injection: 1), and 7 participants when using FlexTouch (preparation: 2; 
      pre-injection set-up: 2; injection: 5). There was 1 repeat per person for Ateos 
      injections versus multiple repeats for FlexTouch injections.Conclusions:Post-hoc 
      analysis demonstrates the time needed for overall administration was shorter for 
      Ateos than FlexTouch, and time for each procedure was shorter or similar for 
      Ateos versus FlexTouch. Ateos was easy for participants with T2DM to learn with 
      fewer repeated steps due to procedural errors, and easy for healthcare 
      professionals to introduce to their patients.
FAU - Asakura, Toshinari
AU  - Asakura T
AD  - Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied 
      Life Sciences, Niigata, Japan.
FAU - Yamazaki, Toshinobu
AU  - Yamazaki T
AD  - Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied 
      Life Sciences, Niigata, Japan.
FAU - Cai, Zhihong
AU  - Cai Z
AD  - Statistical Science, Medicines Development Unit-Japan, Eli Lilly Japan K.K, Kobe, 
      Japan.
FAU - Aranishi, Toshihiko
AU  - Aranishi T
AUID- ORCID: 0000-0001-8862-9468
AD  - Health Outcomes, Health Technology Assessment, Real World Evidence, Medicines 
      Development Unit-Japan, Eli Lilly Japan K.K., Kobe, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200319
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 54Q18076QB (insulin degludec)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Female
MH  - Glucagon-Like Peptides/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Immunoglobulin Fc Fragments/*administration & dosage
MH  - Injections
MH  - Insulin, Long-Acting/*administration & dosage
MH  - Learning
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Self Administration
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - dulaglutide
OT  - insulin degludec
OT  - self-administration
OT  - self-injection
EDAT- 2020/03/07 06:00
MHDA- 2021/03/12 06:00
CRDT- 2020/03/07 06:00
PHST- 2020/03/07 06:00 [pubmed]
PHST- 2021/03/12 06:00 [medline]
PHST- 2020/03/07 06:00 [entrez]
AID - 10.1080/03007995.2020.1739636 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2020 May;36(5):765-769. doi: 10.1080/03007995.2020.1739636. 
      Epub 2020 Mar 19.